Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Adel Mandl
Yale University Cancer Center LAO
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
46 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
- Banner University Medical Center - Tucson
Tucson, Arizona, United States
- University of Arizona Cancer Center-North Campus
Tucson, Arizona, United States
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
- Los Angeles General Medical Center
Los Angeles, California, United States
- Usc / Norris Comprehensive Cancer Center
Los Angeles, California, United States
- Uc Irvine Health/chao Family Comprehensive Cancer Center
Orange, California, United States
- Medstar Georgetown University Hospital
Washington D.C., District of Columbia, United States
- Sibley Memorial Hospital
Washington D.C., District of Columbia, United States
- Uf Health Cancer Institute - Gainesville
Gainesville, Florida, United States
- Moffitt Cancer Center
Tampa, Florida, United States
- Northwestern University
Chicago, Illinois, United States
- University of Kansas Clinical Research Center
Fairway, Kansas, United States
- Haysmed
Hays, Kansas, United States
- Lawrence Memorial Hospital
Lawrence, Kansas, United States
- the University of Kansas Cancer Center - Olathe
Olathe, Kansas, United States
- University of Kansas Cancer Center-Overland Park
Overland Park, Kansas, United States
- Mercy Hospital Pittsburg
Pittsburg, Kansas, United States
- Salina Regional Health Center
Salina, Kansas, United States
- University of Kansas Health System Saint Francis Campus
Topeka, Kansas, United States
- University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, United States
- University of Kentucky/markey Cancer Center
Lexington, Kentucky, United States
- Johns Hopkins University/sidney Kimmel Cancer Center
Baltimore, Maryland, United States
- Wayne State University/karmanos Cancer Institute
Detroit, Michigan, United States
- Weisberg Cancer Treatment Center
Farmington Hills, Michigan, United States
- Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri, United States
- Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, United States
- University Health Truman Medical Center
Kansas City, Missouri, United States
- University of Kansas Cancer Center - North
Kansas City, Missouri, United States
- University of Kansas Cancer Center - Lee'S Summit
Lee's Summit, Missouri, United States
- University of Kansas Cancer Center at North Kansas City Hospital
North Kansas City, Missouri, United States
- Siteman Cancer Center at Christian Hospital
St Louis, Missouri, United States
- Siteman Cancer Center-South County
St Louis, Missouri, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Dartmouth Hitchcock Medical Center/dartmouth Cancer Center
Lebanon, New Hampshire, United States
- Wake Forest University at Clemmons
Clemmons, North Carolina, United States
- Wake Forest Baptist Health - Wilkes Medical Center
Wilkesboro, North Carolina, United States
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 6 Aug 2020
- Primary completion
- 10 Jan 2025
- Completion
- 19 Aug 2026
- Last update posted
- 13 Apr 2026
- Registered enrollment
- 17
- Registry id
- NCT04079712
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.